Haemolytic anaemia in an HIV-infected patient with severe falciparum malaria after treatment with oral artemether-lumefantrine View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2012-03-27

AUTHORS

Angela Corpolongo, Pasquale De Nardo, Piero Ghirga, Elisa Gentilotti, Rita Bellagamba, Chiara Tommasi, Maria Grazia Paglia, Emanuele Nicastri, Pasquale Narciso

ABSTRACT

Intravenous (i.v.) artesunate is now the recommended first-line treatment of severe falciparum malaria in adults and children by WHO guidelines. Nevertheless, several cases of haemolytic anaemia due to i.v. artesunate treatment have been reported. This paper describes the case of an HIV-infected patient with severe falciparum malaria who was diagnosed with haemolytic anaemia after treatment with oral artemether-lumefantrine.The patient presented with fever, headache, and arthromyalgia after returning from Central African Republic where he had been working. The blood examination revealed acute renal failure, thrombocytopaenia and hypoxia. Blood for malaria parasites indicated hyperparasitaemia (6%) and Plasmodium falciparum infection was confirmed by nested-PCR. Severe malaria according to the laboratory WHO criteria was diagnosed. A treatment with quinine and doxycycline for the first 12 hours was initially administered, followed by arthemeter/lumefantrine (Riamet(®)) for a further three days. At day 10, a diagnosis of severe haemolytic anaemia was made (Hb 6.9 g/dl, LDH 2071 U/l). Hereditary and autoimmune disorders and other infections were excluded through bone marrow aspiration, total body TC scan and a wide panel of molecular and serologic assays. The patient was treated by transfusion of six units of packed blood red cell. He was discharged after complete remission at day 25. At present, the patient is in a good clinical condition and there is no evidence of haemolytic anaemia recurrence.This is the first report of haemolytic anaemia probably associated with oral artemether/lumefantrine. Further research is warranted to better define the adverse events occurring during combination therapy with artemisinin derivatives. More... »

PAGES

91-91

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/1475-2875-11-91

DOI

http://dx.doi.org/10.1186/1475-2875-11-91

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1014109697

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/22453057


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1108", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical Microbiology", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Administration, Oral", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Anemia, Hemolytic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antimalarials", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Artemether, Lumefantrine Drug Combination", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Artemisinins", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Coinfection", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Combinations", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Therapy, Combination", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Erythrocytes", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Ethanolamines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Fluorenes", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "HIV", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "HIV Infections", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hemolysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Malaria, Falciparum", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Plasmodium falciparum", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Severity of Illness Index", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "National Institute for Infectious Diseases \"Lazzaro Spallanzani\", Via Portuense 292, 00149 Rome, Italy", 
          "id": "http://www.grid.ac/institutes/grid.419423.9", 
          "name": [
            "National Institute for Infectious Diseases \"Lazzaro Spallanzani\", Via Portuense 292, 00149 Rome, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Corpolongo", 
        "givenName": "Angela", 
        "id": "sg:person.0622421657.38", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0622421657.38"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "National Institute for Infectious Diseases \"Lazzaro Spallanzani\", Via Portuense 292, 00149 Rome, Italy", 
          "id": "http://www.grid.ac/institutes/grid.419423.9", 
          "name": [
            "National Institute for Infectious Diseases \"Lazzaro Spallanzani\", Via Portuense 292, 00149 Rome, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "De Nardo", 
        "givenName": "Pasquale", 
        "id": "sg:person.0674412415.06", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0674412415.06"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "National Institute for Infectious Diseases \"Lazzaro Spallanzani\", Via Portuense 292, 00149 Rome, Italy", 
          "id": "http://www.grid.ac/institutes/grid.419423.9", 
          "name": [
            "National Institute for Infectious Diseases \"Lazzaro Spallanzani\", Via Portuense 292, 00149 Rome, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ghirga", 
        "givenName": "Piero", 
        "id": "sg:person.0633063045.32", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0633063045.32"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "National Institute for Infectious Diseases \"Lazzaro Spallanzani\", Via Portuense 292, 00149 Rome, Italy", 
          "id": "http://www.grid.ac/institutes/grid.419423.9", 
          "name": [
            "National Institute for Infectious Diseases \"Lazzaro Spallanzani\", Via Portuense 292, 00149 Rome, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gentilotti", 
        "givenName": "Elisa", 
        "id": "sg:person.0623244161.01", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0623244161.01"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "National Institute for Infectious Diseases \"Lazzaro Spallanzani\", Via Portuense 292, 00149 Rome, Italy", 
          "id": "http://www.grid.ac/institutes/grid.419423.9", 
          "name": [
            "National Institute for Infectious Diseases \"Lazzaro Spallanzani\", Via Portuense 292, 00149 Rome, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bellagamba", 
        "givenName": "Rita", 
        "id": "sg:person.0647671457.37", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0647671457.37"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "National Institute for Infectious Diseases \"Lazzaro Spallanzani\", Via Portuense 292, 00149 Rome, Italy", 
          "id": "http://www.grid.ac/institutes/grid.419423.9", 
          "name": [
            "National Institute for Infectious Diseases \"Lazzaro Spallanzani\", Via Portuense 292, 00149 Rome, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tommasi", 
        "givenName": "Chiara", 
        "id": "sg:person.01045744574.20", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01045744574.20"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "National Institute for Infectious Diseases \"Lazzaro Spallanzani\", Via Portuense 292, 00149 Rome, Italy", 
          "id": "http://www.grid.ac/institutes/grid.419423.9", 
          "name": [
            "National Institute for Infectious Diseases \"Lazzaro Spallanzani\", Via Portuense 292, 00149 Rome, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Paglia", 
        "givenName": "Maria Grazia", 
        "id": "sg:person.0730561007.68", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0730561007.68"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "National Institute for Infectious Diseases \"Lazzaro Spallanzani\", Via Portuense 292, 00149 Rome, Italy", 
          "id": "http://www.grid.ac/institutes/grid.419423.9", 
          "name": [
            "National Institute for Infectious Diseases \"Lazzaro Spallanzani\", Via Portuense 292, 00149 Rome, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nicastri", 
        "givenName": "Emanuele", 
        "id": "sg:person.01160152235.27", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01160152235.27"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "National Institute for Infectious Diseases \"Lazzaro Spallanzani\", Via Portuense 292, 00149 Rome, Italy", 
          "id": "http://www.grid.ac/institutes/grid.419423.9", 
          "name": [
            "National Institute for Infectious Diseases \"Lazzaro Spallanzani\", Via Portuense 292, 00149 Rome, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Narciso", 
        "givenName": "Pasquale", 
        "id": "sg:person.01220541041.15", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01220541041.15"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2012-03-27", 
    "datePublishedReg": "2012-03-27", 
    "description": "Intravenous (i.v.) artesunate is now the recommended first-line treatment of severe falciparum malaria in adults and children by WHO guidelines. Nevertheless, several cases of haemolytic anaemia due to i.v. artesunate treatment have been reported. This paper describes the case of an HIV-infected patient with severe falciparum malaria who was diagnosed with haemolytic anaemia after treatment with oral artemether-lumefantrine.The patient presented with fever, headache, and arthromyalgia after returning from Central African Republic where he had been working. The blood examination revealed acute renal failure, thrombocytopaenia and hypoxia. Blood for malaria parasites indicated hyperparasitaemia (6%) and Plasmodium falciparum infection was confirmed by nested-PCR. Severe malaria according to the laboratory WHO criteria was diagnosed. A treatment with quinine and doxycycline for the first 12 hours was initially administered, followed by arthemeter/lumefantrine (Riamet(\u00ae)) for a further three days. At day 10, a diagnosis of severe haemolytic anaemia was made (Hb 6.9 g/dl, LDH 2071 U/l). Hereditary and autoimmune disorders and other infections were excluded through bone marrow aspiration, total body TC scan and a wide panel of molecular and serologic assays. The patient was treated by transfusion of six units of packed blood red cell. He was discharged after complete remission at day 25. At present, the patient is in a good clinical condition and there is no evidence of haemolytic anaemia recurrence.This is the first report of haemolytic anaemia probably associated with oral artemether/lumefantrine. Further research is warranted to better define the adverse events occurring during combination therapy with artemisinin derivatives.", 
    "genre": "article", 
    "id": "sg:pub.10.1186/1475-2875-11-91", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1030597", 
        "issn": [
          "1475-2875"
        ], 
        "name": "Malaria Journal", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "11"
      }
    ], 
    "keywords": [
      "severe falciparum malaria", 
      "falciparum malaria", 
      "haemolytic anaemia", 
      "good clinical condition", 
      "first-line treatment", 
      "acute renal failure", 
      "artemether/lumefantrine", 
      "Plasmodium falciparum infection", 
      "bone marrow aspiration", 
      "severe haemolytic anaemia", 
      "intravenous artesunate", 
      "TC scan", 
      "artesunate treatment", 
      "complete remission", 
      "artemether-lumefantrine", 
      "renal failure", 
      "falciparum infection", 
      "severe malaria", 
      "adverse events", 
      "blood examination", 
      "autoimmune disorders", 
      "marrow aspiration", 
      "combination therapy", 
      "blood red cells", 
      "serologic assays", 
      "clinical conditions", 
      "artemisinin derivatives", 
      "patients", 
      "anemia", 
      "day 10", 
      "day 25", 
      "malaria parasites", 
      "malaria", 
      "red cells", 
      "treatment", 
      "HIV", 
      "lumefantrine", 
      "infection", 
      "wide panel", 
      "first report", 
      "further research", 
      "hyperparasitaemia", 
      "arthromyalgia", 
      "thrombocytopaenia", 
      "remission", 
      "transfusion", 
      "headache", 
      "fever", 
      "recurrence", 
      "artesunate", 
      "therapy", 
      "Central African Republic", 
      "doxycycline", 
      "diagnosis", 
      "blood", 
      "hypoxia", 
      "disorders", 
      "adults", 
      "scans", 
      "children", 
      "quinine", 
      "cases", 
      "examination", 
      "African Republic", 
      "days", 
      "report", 
      "hours", 
      "PCR", 
      "guidelines", 
      "assays", 
      "aspiration", 
      "parasites", 
      "cells", 
      "failure", 
      "evidence", 
      "criteria", 
      "events", 
      "panel", 
      "laboratory", 
      "units", 
      "present", 
      "research", 
      "conditions", 
      "derivatives", 
      "Republic", 
      "paper", 
      "oral artemether-lumefantrine", 
      "arthemeter/lumefantrine", 
      "total body TC scan", 
      "body TC scan", 
      "packed blood red cell", 
      "haemolytic anaemia recurrence", 
      "anaemia recurrence", 
      "oral artemether/lumefantrine"
    ], 
    "name": "Haemolytic anaemia in an HIV-infected patient with severe falciparum malaria after treatment with oral artemether-lumefantrine", 
    "pagination": "91-91", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1014109697"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/1475-2875-11-91"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "22453057"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/1475-2875-11-91", 
      "https://app.dimensions.ai/details/publication/pub.1014109697"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-12-01T19:28", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211201/entities/gbq_results/article/article_580.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1186/1475-2875-11-91"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/1475-2875-11-91'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/1475-2875-11-91'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/1475-2875-11-91'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/1475-2875-11-91'


 

This table displays all metadata directly associated to this object as RDF triples.

295 TRIPLES      21 PREDICATES      141 URIs      132 LITERALS      27 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/1475-2875-11-91 schema:about N0c259872795046e681ae53c7bf2278a4
2 N1efcb774889848e796908ff953a0a666
3 N2524740c8dab48149cfea1c405392463
4 N2af3f1137f834c309ddf8d417fce99f6
5 N330aab910a494c3693dedf12fa7a462c
6 N3a03f7944b0d4f459558ff2925fc5494
7 N4ba610c90f6e4d80970cb76b51ad85f0
8 N570b5c10d4f34bb794452faf6e24b130
9 N6adf0f2eeafc45a0b68e2a1fb400e45d
10 N7ea6fbe7b3a1486bacaa6e93db3e61f1
11 Nc582d3458c694161bcef0d3205ce0c0a
12 Nce8b08247a4a452cbee46147128f979a
13 Ncf13aa5c685a41d5912b234b5be16560
14 Nd4e1b30137fd4e39a9cdd2b38992bc0c
15 Nd57de78eeb7b44cb86f39ad5136dd5b8
16 Nde4d0e20cae843bc91bf0d34524c8745
17 Neb9de97479824564bb1a7f389f50c39d
18 Nf1ef1720500448018942c5b62e84fb52
19 Nf469d3ff368b4a7abffb3984b8120d2e
20 Nf859132d87b846cb938898a3d2a0e42c
21 anzsrc-for:11
22 anzsrc-for:1103
23 anzsrc-for:1108
24 schema:author Nc217f79d79fc450c80882182ed65659c
25 schema:datePublished 2012-03-27
26 schema:datePublishedReg 2012-03-27
27 schema:description Intravenous (i.v.) artesunate is now the recommended first-line treatment of severe falciparum malaria in adults and children by WHO guidelines. Nevertheless, several cases of haemolytic anaemia due to i.v. artesunate treatment have been reported. This paper describes the case of an HIV-infected patient with severe falciparum malaria who was diagnosed with haemolytic anaemia after treatment with oral artemether-lumefantrine.The patient presented with fever, headache, and arthromyalgia after returning from Central African Republic where he had been working. The blood examination revealed acute renal failure, thrombocytopaenia and hypoxia. Blood for malaria parasites indicated hyperparasitaemia (6%) and Plasmodium falciparum infection was confirmed by nested-PCR. Severe malaria according to the laboratory WHO criteria was diagnosed. A treatment with quinine and doxycycline for the first 12 hours was initially administered, followed by arthemeter/lumefantrine (Riamet(®)) for a further three days. At day 10, a diagnosis of severe haemolytic anaemia was made (Hb 6.9 g/dl, LDH 2071 U/l). Hereditary and autoimmune disorders and other infections were excluded through bone marrow aspiration, total body TC scan and a wide panel of molecular and serologic assays. The patient was treated by transfusion of six units of packed blood red cell. He was discharged after complete remission at day 25. At present, the patient is in a good clinical condition and there is no evidence of haemolytic anaemia recurrence.This is the first report of haemolytic anaemia probably associated with oral artemether/lumefantrine. Further research is warranted to better define the adverse events occurring during combination therapy with artemisinin derivatives.
28 schema:genre article
29 schema:inLanguage en
30 schema:isAccessibleForFree true
31 schema:isPartOf N9d05bbae9e2047438b64ecffa69dec1b
32 Nf7d4b70e69764c09ade7da139aaf23ab
33 sg:journal.1030597
34 schema:keywords African Republic
35 Central African Republic
36 HIV
37 PCR
38 Plasmodium falciparum infection
39 Republic
40 TC scan
41 acute renal failure
42 adults
43 adverse events
44 anaemia recurrence
45 anemia
46 artemether-lumefantrine
47 artemether/lumefantrine
48 artemisinin derivatives
49 artesunate
50 artesunate treatment
51 arthemeter/lumefantrine
52 arthromyalgia
53 aspiration
54 assays
55 autoimmune disorders
56 blood
57 blood examination
58 blood red cells
59 body TC scan
60 bone marrow aspiration
61 cases
62 cells
63 children
64 clinical conditions
65 combination therapy
66 complete remission
67 conditions
68 criteria
69 day 10
70 day 25
71 days
72 derivatives
73 diagnosis
74 disorders
75 doxycycline
76 events
77 evidence
78 examination
79 failure
80 falciparum infection
81 falciparum malaria
82 fever
83 first report
84 first-line treatment
85 further research
86 good clinical condition
87 guidelines
88 haemolytic anaemia
89 haemolytic anaemia recurrence
90 headache
91 hours
92 hyperparasitaemia
93 hypoxia
94 infection
95 intravenous artesunate
96 laboratory
97 lumefantrine
98 malaria
99 malaria parasites
100 marrow aspiration
101 oral artemether-lumefantrine
102 oral artemether/lumefantrine
103 packed blood red cell
104 panel
105 paper
106 parasites
107 patients
108 present
109 quinine
110 recurrence
111 red cells
112 remission
113 renal failure
114 report
115 research
116 scans
117 serologic assays
118 severe falciparum malaria
119 severe haemolytic anaemia
120 severe malaria
121 therapy
122 thrombocytopaenia
123 total body TC scan
124 transfusion
125 treatment
126 units
127 wide panel
128 schema:name Haemolytic anaemia in an HIV-infected patient with severe falciparum malaria after treatment with oral artemether-lumefantrine
129 schema:pagination 91-91
130 schema:productId N4be2a642626e472d9e49fd5a38c588f6
131 N531b7e38b5c747168b43d2c379f25acc
132 Nd66d9f2dd4604a5097070368b131538b
133 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014109697
134 https://doi.org/10.1186/1475-2875-11-91
135 schema:sdDatePublished 2021-12-01T19:28
136 schema:sdLicense https://scigraph.springernature.com/explorer/license/
137 schema:sdPublisher N522c82b12c5a4cecb761f23e140f5011
138 schema:url https://doi.org/10.1186/1475-2875-11-91
139 sgo:license sg:explorer/license/
140 sgo:sdDataset articles
141 rdf:type schema:ScholarlyArticle
142 N0c259872795046e681ae53c7bf2278a4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name Severity of Illness Index
144 rdf:type schema:DefinedTerm
145 N1efcb774889848e796908ff953a0a666 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
146 schema:name Fluorenes
147 rdf:type schema:DefinedTerm
148 N2524740c8dab48149cfea1c405392463 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name Hemolysis
150 rdf:type schema:DefinedTerm
151 N2af3f1137f834c309ddf8d417fce99f6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Administration, Oral
153 rdf:type schema:DefinedTerm
154 N330aab910a494c3693dedf12fa7a462c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Plasmodium falciparum
156 rdf:type schema:DefinedTerm
157 N3a03f7944b0d4f459558ff2925fc5494 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
158 schema:name Drug Therapy, Combination
159 rdf:type schema:DefinedTerm
160 N4ba610c90f6e4d80970cb76b51ad85f0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
161 schema:name Coinfection
162 rdf:type schema:DefinedTerm
163 N4be2a642626e472d9e49fd5a38c588f6 schema:name doi
164 schema:value 10.1186/1475-2875-11-91
165 rdf:type schema:PropertyValue
166 N4e69ecc0cf904ccaa18c8c423a7970c5 rdf:first sg:person.01160152235.27
167 rdf:rest Nb8efa3019f9446c38cfe227b17497632
168 N522c82b12c5a4cecb761f23e140f5011 schema:name Springer Nature - SN SciGraph project
169 rdf:type schema:Organization
170 N531b7e38b5c747168b43d2c379f25acc schema:name pubmed_id
171 schema:value 22453057
172 rdf:type schema:PropertyValue
173 N570b5c10d4f34bb794452faf6e24b130 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
174 schema:name Anemia, Hemolytic
175 rdf:type schema:DefinedTerm
176 N63acac005bf34de585fb064012a3d4ff rdf:first sg:person.0730561007.68
177 rdf:rest N4e69ecc0cf904ccaa18c8c423a7970c5
178 N6adf0f2eeafc45a0b68e2a1fb400e45d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
179 schema:name Humans
180 rdf:type schema:DefinedTerm
181 N7c79e486b03841219de3a3244ce36e84 rdf:first sg:person.01045744574.20
182 rdf:rest N63acac005bf34de585fb064012a3d4ff
183 N7ea6fbe7b3a1486bacaa6e93db3e61f1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
184 schema:name HIV Infections
185 rdf:type schema:DefinedTerm
186 N88f9c36df8ef4392a83008649ac7b2dd rdf:first sg:person.0674412415.06
187 rdf:rest Nc1ef67e3ae574fc29b5adeab53b19ab2
188 N9d05bbae9e2047438b64ecffa69dec1b schema:volumeNumber 11
189 rdf:type schema:PublicationVolume
190 Nb4cea1c45fd24321a6d9b49f8996ab73 rdf:first sg:person.0647671457.37
191 rdf:rest N7c79e486b03841219de3a3244ce36e84
192 Nb8efa3019f9446c38cfe227b17497632 rdf:first sg:person.01220541041.15
193 rdf:rest rdf:nil
194 Nc1ef67e3ae574fc29b5adeab53b19ab2 rdf:first sg:person.0633063045.32
195 rdf:rest Nc3d2777071b44b859987ba24378bfed8
196 Nc217f79d79fc450c80882182ed65659c rdf:first sg:person.0622421657.38
197 rdf:rest N88f9c36df8ef4392a83008649ac7b2dd
198 Nc3d2777071b44b859987ba24378bfed8 rdf:first sg:person.0623244161.01
199 rdf:rest Nb4cea1c45fd24321a6d9b49f8996ab73
200 Nc582d3458c694161bcef0d3205ce0c0a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
201 schema:name HIV
202 rdf:type schema:DefinedTerm
203 Nce8b08247a4a452cbee46147128f979a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
204 schema:name Drug Combinations
205 rdf:type schema:DefinedTerm
206 Ncf13aa5c685a41d5912b234b5be16560 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
207 schema:name Male
208 rdf:type schema:DefinedTerm
209 Nd4e1b30137fd4e39a9cdd2b38992bc0c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
210 schema:name Malaria, Falciparum
211 rdf:type schema:DefinedTerm
212 Nd57de78eeb7b44cb86f39ad5136dd5b8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
213 schema:name Adult
214 rdf:type schema:DefinedTerm
215 Nd66d9f2dd4604a5097070368b131538b schema:name dimensions_id
216 schema:value pub.1014109697
217 rdf:type schema:PropertyValue
218 Nde4d0e20cae843bc91bf0d34524c8745 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
219 schema:name Ethanolamines
220 rdf:type schema:DefinedTerm
221 Neb9de97479824564bb1a7f389f50c39d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
222 schema:name Erythrocytes
223 rdf:type schema:DefinedTerm
224 Nf1ef1720500448018942c5b62e84fb52 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
225 schema:name Artemisinins
226 rdf:type schema:DefinedTerm
227 Nf469d3ff368b4a7abffb3984b8120d2e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
228 schema:name Antimalarials
229 rdf:type schema:DefinedTerm
230 Nf7d4b70e69764c09ade7da139aaf23ab schema:issueNumber 1
231 rdf:type schema:PublicationIssue
232 Nf859132d87b846cb938898a3d2a0e42c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
233 schema:name Artemether, Lumefantrine Drug Combination
234 rdf:type schema:DefinedTerm
235 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
236 schema:name Medical and Health Sciences
237 rdf:type schema:DefinedTerm
238 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
239 schema:name Clinical Sciences
240 rdf:type schema:DefinedTerm
241 anzsrc-for:1108 schema:inDefinedTermSet anzsrc-for:
242 schema:name Medical Microbiology
243 rdf:type schema:DefinedTerm
244 sg:journal.1030597 schema:issn 1475-2875
245 schema:name Malaria Journal
246 schema:publisher Springer Nature
247 rdf:type schema:Periodical
248 sg:person.01045744574.20 schema:affiliation grid-institutes:grid.419423.9
249 schema:familyName Tommasi
250 schema:givenName Chiara
251 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01045744574.20
252 rdf:type schema:Person
253 sg:person.01160152235.27 schema:affiliation grid-institutes:grid.419423.9
254 schema:familyName Nicastri
255 schema:givenName Emanuele
256 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01160152235.27
257 rdf:type schema:Person
258 sg:person.01220541041.15 schema:affiliation grid-institutes:grid.419423.9
259 schema:familyName Narciso
260 schema:givenName Pasquale
261 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01220541041.15
262 rdf:type schema:Person
263 sg:person.0622421657.38 schema:affiliation grid-institutes:grid.419423.9
264 schema:familyName Corpolongo
265 schema:givenName Angela
266 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0622421657.38
267 rdf:type schema:Person
268 sg:person.0623244161.01 schema:affiliation grid-institutes:grid.419423.9
269 schema:familyName Gentilotti
270 schema:givenName Elisa
271 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0623244161.01
272 rdf:type schema:Person
273 sg:person.0633063045.32 schema:affiliation grid-institutes:grid.419423.9
274 schema:familyName Ghirga
275 schema:givenName Piero
276 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0633063045.32
277 rdf:type schema:Person
278 sg:person.0647671457.37 schema:affiliation grid-institutes:grid.419423.9
279 schema:familyName Bellagamba
280 schema:givenName Rita
281 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0647671457.37
282 rdf:type schema:Person
283 sg:person.0674412415.06 schema:affiliation grid-institutes:grid.419423.9
284 schema:familyName De Nardo
285 schema:givenName Pasquale
286 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0674412415.06
287 rdf:type schema:Person
288 sg:person.0730561007.68 schema:affiliation grid-institutes:grid.419423.9
289 schema:familyName Paglia
290 schema:givenName Maria Grazia
291 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0730561007.68
292 rdf:type schema:Person
293 grid-institutes:grid.419423.9 schema:alternateName National Institute for Infectious Diseases "Lazzaro Spallanzani", Via Portuense 292, 00149 Rome, Italy
294 schema:name National Institute for Infectious Diseases "Lazzaro Spallanzani", Via Portuense 292, 00149 Rome, Italy
295 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...